US4554101A
(en)
|
1981-01-09 |
1985-11-19 |
New York Blood Center, Inc. |
Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
|
US4798824A
(en)
|
1985-10-03 |
1989-01-17 |
Wisconsin Alumni Research Foundation |
Perfusate for the preservation of organs
|
US4873192A
(en)
|
1987-02-17 |
1989-10-10 |
The United States Of America As Represented By The Department Of Health And Human Services |
Process for site specific mutagenesis without phenotypic selection
|
JP3040121B2
(en)
|
1988-01-12 |
2000-05-08 |
ジェネンテク,インコーポレイテッド |
Methods of treating tumor cells by inhibiting growth factor receptor function
|
US5720937A
(en)
|
1988-01-12 |
1998-02-24 |
Genentech, Inc. |
In vivo tumor detection assay
|
US5906936A
(en)
|
1988-05-04 |
1999-05-25 |
Yeda Research And Development Co. Ltd. |
Endowing lymphocytes with antibody specificity
|
US6534055B1
(en)
|
1988-11-23 |
2003-03-18 |
Genetics Institute, Inc. |
Methods for selectively stimulating proliferation of T cells
|
US6352694B1
(en)
|
1994-06-03 |
2002-03-05 |
Genetics Institute, Inc. |
Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
|
US6905680B2
(en)
|
1988-11-23 |
2005-06-14 |
Genetics Institute, Inc. |
Methods of treating HIV infected subjects
|
US5858358A
(en)
|
1992-04-07 |
1999-01-12 |
The United States Of America As Represented By The Secretary Of The Navy |
Methods for selectively stimulating proliferation of T cells
|
US5665577A
(en)
|
1989-02-06 |
1997-09-09 |
Dana-Farber Cancer Institute |
Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof
|
DE3920358A1
(en)
|
1989-06-22 |
1991-01-17 |
Behringwerke Ag |
BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
|
US5283173A
(en)
|
1990-01-24 |
1994-02-01 |
The Research Foundation Of State University Of New York |
System to detect protein-protein interactions
|
CA2096222C
(en)
|
1990-11-13 |
1998-12-29 |
Stephen D. Lupton |
Bifunctional selectable fusion genes
|
US6319494B1
(en)
|
1990-12-14 |
2001-11-20 |
Cell Genesys, Inc. |
Chimeric chains for receptor-associated signal transduction pathways
|
US5843728A
(en)
|
1991-03-07 |
1998-12-01 |
The General Hospital Corporation |
Redirection of cellular immunity by receptor chimeras
|
US5190556A
(en)
|
1991-03-19 |
1993-03-02 |
O.B. Tech, Inc. |
Cord cutter sampler
|
US5851795A
(en)
*
|
1991-06-27 |
1998-12-22 |
Bristol-Myers Squibb Company |
Soluble CTLA4 molecules and uses thereof
|
GB9114948D0
(en)
|
1991-07-11 |
1991-08-28 |
Pfizer Ltd |
Process for preparing sertraline intermediates
|
US8211422B2
(en)
|
1992-03-18 |
2012-07-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Chimeric receptor genes and cells transformed therewith
|
IL104570A0
(en)
|
1992-03-18 |
1993-05-13 |
Yeda Res & Dev |
Chimeric genes and cells transformed therewith
|
US5552267A
(en)
|
1992-04-03 |
1996-09-03 |
The Trustees Of Columbia University In The City Of New York |
Solution for prolonged organ preservation
|
US6005079A
(en)
|
1992-08-21 |
1999-12-21 |
Vrije Universiteit Brussels |
Immunoglobulins devoid of light chains
|
DK1589107T3
(en)
|
1992-08-21 |
2010-04-26 |
Univ Bruxelles |
Immunuglobulins without light chains
|
US5629327A
(en)
|
1993-03-01 |
1997-05-13 |
Childrens Hospital Medical Center Corp. |
Methods and compositions for inhibition of angiogenesis
|
DK0698097T3
(en)
|
1993-04-29 |
2001-10-08 |
Unilever Nv |
Production of antibodies or (functionalized) fragments thereof derived from Camelidae heavy chain immunoglobulins
|
EP0804590A1
(en)
|
1993-05-21 |
1997-11-05 |
Targeted Genetics Corporation |
Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
|
US5698579A
(en)
|
1993-07-02 |
1997-12-16 |
Celgene Corporation |
Cyclic amides
|
US5372581A
(en)
|
1993-07-21 |
1994-12-13 |
Minneapolis Children's Services Corporation |
Method and apparatus for placental blood collection
|
JPH07291996A
(en)
*
|
1994-03-01 |
1995-11-07 |
Yuu Honshiyo |
Polypeptide related to programmed cell death in human, dna coding the same, vector consisting of the same dna, host cell transformed with the same vector, antibody of the same polypeptide and pharmaceutical composition containing the same polypeptide or the same antibody
|
US7175843B2
(en)
|
1994-06-03 |
2007-02-13 |
Genetics Institute, Llc |
Methods for selectively stimulating proliferation of T cells
|
US6309853B1
(en)
|
1994-08-17 |
2001-10-30 |
The Rockfeller University |
Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
|
US5827642A
(en)
|
1994-08-31 |
1998-10-27 |
Fred Hutchinson Cancer Research Center |
Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
|
EP0787188A1
(en)
*
|
1994-11-01 |
1997-08-06 |
Targeted Genetics Corporation |
Chimeric receptors for the generation of selectively-activatable t h?-independent cytotoxic t cells
|
US5712149A
(en)
*
|
1995-02-03 |
1998-01-27 |
Cell Genesys, Inc. |
Chimeric receptor molecules for delivery of co-stimulatory signals
|
US6103521A
(en)
|
1995-02-06 |
2000-08-15 |
Cell Genesys, Inc. |
Multispecific chimeric receptors
|
US5783404A
(en)
|
1995-04-13 |
1998-07-21 |
Amgen Inc. |
Methods and compositions for determining HER-2/neu expression using monoclonal antibodies
|
US7067318B2
(en)
|
1995-06-07 |
2006-06-27 |
The Regents Of The University Of Michigan |
Methods for transfecting T cells
|
US6692964B1
(en)
|
1995-05-04 |
2004-02-17 |
The United States Of America As Represented By The Secretary Of The Navy |
Methods for transfecting T cells
|
US6013516A
(en)
|
1995-10-06 |
2000-01-11 |
The Salk Institute For Biological Studies |
Vector and method of use for nucleic acid delivery to non-dividing cells
|
US5948893A
(en)
|
1996-01-17 |
1999-09-07 |
The United States Of America As Represented By The Secretary Of The Navy |
Murine hybridoma and antibody binding to CD28 receptor secreted by the hybridoma and method of using the antibody
|
US5635517B1
(en)
|
1996-07-24 |
1999-06-29 |
Celgene Corp |
Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
|
US5798368A
(en)
|
1996-08-22 |
1998-08-25 |
Celgene Corporation |
Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNFα levels
|
US6281230B1
(en)
|
1996-07-24 |
2001-08-28 |
Celgene Corporation |
Isoindolines, method of use, and pharmaceutical compositions
|
SK9199A3
(en)
|
1996-07-24 |
1999-07-12 |
Celgene Corp |
2,6-dioxopiperidines, pharmaceutical composition them containing and their use
|
NZ334148A
(en)
|
1996-08-12 |
2001-12-21 |
Celgene Corp |
3-Substituted phenyl-ethyl or ethenyl derivatives terminated with a nitrile, alkane, carboxyl or carbamoyl group useful to reduce cytokine levels
|
US6541212B2
(en)
|
1997-03-10 |
2003-04-01 |
The Regents Of The University Of California |
Methods for detecting prostate stem cell antigen protein
|
US5874448A
(en)
|
1997-11-18 |
1999-02-23 |
Celgene Corporation |
Substituted 2-(2,6 dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing TNFα levels
|
US5994136A
(en)
|
1997-12-12 |
1999-11-30 |
Cell Genesys, Inc. |
Method and means for producing high titer, safe, recombinant lentivirus vectors
|
FR2777909B1
(en)
|
1998-04-24 |
2002-08-02 |
Pasteur Institut |
USE OF TRIPLEX-STRUCTURED DNA SEQUENCES FOR THE TRANSFER OF NUCLEOTID SEQUENCES IN CELLS, RECOMBINANT VECTORS CONTAINING THESE TRIPLEX SEQUENCES
|
AU2472400A
(en)
|
1998-10-20 |
2000-05-08 |
City Of Hope |
CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
|
EP1171596A1
(en)
|
1999-04-16 |
2002-01-16 |
Celltech Therapeutics Limited |
Synthetic transmembrane components
|
GB9908816D0
(en)
|
1999-04-16 |
1999-06-09 |
Celltech Therapeutics Ltd |
Biological product
|
KR100696407B1
(en)
|
1999-04-16 |
2007-03-19 |
더블유엠. 마쉬 라이스 유니버시티 |
Biodegradable polypropylene fumarate networks cross linked with polypropylene fumarate-diacrylate macromers
|
EP1849873B1
(en)
|
1999-04-29 |
2011-10-12 |
Gbp Ip, Llc |
Method and means for producing high titer, safe, recombinant lentivirus vectors
|
US6355699B1
(en)
|
1999-06-30 |
2002-03-12 |
Ethicon, Inc. |
Process for manufacturing biomedical foams
|
US7572631B2
(en)
|
2000-02-24 |
2009-08-11 |
Invitrogen Corporation |
Activation and expansion of T cells
|
US6797514B2
(en)
|
2000-02-24 |
2004-09-28 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
US6867041B2
(en)
|
2000-02-24 |
2005-03-15 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
MXPA02008265A
(en)
|
2000-02-24 |
2004-09-10 |
Xcyte Therapies Inc |
Simultaneous stimulation and concentration of cells.
|
JP2002045174A
(en)
|
2000-07-31 |
2002-02-12 |
Inst Of Physical & Chemical Res |
Method for proliferating natural killer cell
|
GB0025307D0
(en)
*
|
2000-10-16 |
2000-11-29 |
Celltech Chiroscience Ltd |
Biological products
|
WO2002036142A2
(en)
*
|
2000-11-03 |
2002-05-10 |
University Of Vermont And State Agricultural College |
Compositions for inhibiting grb7
|
AU2001297703B2
(en)
|
2000-11-07 |
2006-10-19 |
City Of Hope |
CD19-specific redirected immune cells
|
EP2322601A1
(en)
|
2000-12-06 |
2011-05-18 |
Anthrogenesis Corporation |
Method of collecting placental stem cells
|
US7091353B2
(en)
|
2000-12-27 |
2006-08-15 |
Celgene Corporation |
Isoindole-imide compounds, compositions, and uses thereof
|
US20030045552A1
(en)
|
2000-12-27 |
2003-03-06 |
Robarge Michael J. |
Isoindole-imide compounds, compositions, and uses thereof
|
JP2004528021A
(en)
|
2001-02-14 |
2004-09-16 |
アンスロジェネシス コーポレーション |
Postpartum mammalian placenta, its use and placental stem cells derived therefrom
|
US7070995B2
(en)
|
2001-04-11 |
2006-07-04 |
City Of Hope |
CE7-specific redirected immune cells
|
US20090257994A1
(en)
|
2001-04-30 |
2009-10-15 |
City Of Hope |
Chimeric immunoreceptor useful in treating human cancers
|
US7514537B2
(en)
|
2001-04-30 |
2009-04-07 |
City Of Hope |
Chimeric immunoreceptor useful in treating human gliomas
|
WO2002088346A2
(en)
|
2001-05-01 |
2002-11-07 |
National Research Council Of Canada |
A system for inducible expression in eukaryotic cells
|
AUPR617901A0
(en)
|
2001-07-06 |
2001-08-02 |
Pacmab Pty Ltd |
Method for treating multiple myeloma
|
AU2003202908A1
(en)
|
2002-01-03 |
2003-07-24 |
The Trustees Of The University Of Pennsylvania |
Activation and expansion of t-cells using an engineered multivalent signaling platform
|
US20030187515A1
(en)
|
2002-03-26 |
2003-10-02 |
Hariri Robert J. |
Collagen biofabric and methods of preparing and using the collagen biofabric
|
US7498171B2
(en)
|
2002-04-12 |
2009-03-03 |
Anthrogenesis Corporation |
Modulation of stem and progenitor cell differentiation, assays, and uses thereof
|
US7446190B2
(en)
|
2002-05-28 |
2008-11-04 |
Sloan-Kettering Institute For Cancer Research |
Nucleic acids encoding chimeric T cell receptors
|
JP2004113062A
(en)
|
2002-09-25 |
2004-04-15 |
Teruyuki Nagamune |
Animal cell having chimera receptor and its utilization
|
US7541440B2
(en)
|
2002-09-30 |
2009-06-02 |
Immunomedics, Inc. |
Chimeric, human and humanized anti-granulocyte antibodies and methods of use
|
JP4790413B2
(en)
|
2002-10-08 |
2011-10-12 |
イミューノメディクス、インコーポレイテッド |
Antibody therapy
|
GB0225279D0
(en)
*
|
2002-10-30 |
2002-12-11 |
Celltech R&D Ltd |
Biological products
|
US20070155663A1
(en)
|
2003-03-24 |
2007-07-05 |
Rudolf Richter |
Use of chemokine receptor agonists for stem cell transplantation
|
US7541442B2
(en)
|
2003-05-30 |
2009-06-02 |
Agensys, Inc. |
Antibodies and related molecules that bind to PSCA proteins
|
US7595379B2
(en)
|
2003-05-30 |
2009-09-29 |
Agensys, Inc. |
Antibodies and related molecules that bind to PSCA proteins
|
US20050118185A1
(en)
|
2003-06-18 |
2005-06-02 |
Cell Center Cologne Gmbh |
Recombinant immunoreceptors
|
CN104059147A
(en)
|
2003-06-27 |
2014-09-24 |
艾默根佛蒙特有限公司 |
Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
|
US7902338B2
(en)
|
2003-07-31 |
2011-03-08 |
Immunomedics, Inc. |
Anti-CD19 antibodies
|
JP4733635B2
(en)
|
2003-07-31 |
2011-07-27 |
イミューノメディクス、インコーポレイテッド |
Anti-CD19 antibody
|
US7435596B2
(en)
|
2004-11-04 |
2008-10-14 |
St. Jude Children's Research Hospital, Inc. |
Modified cell line and method for expansion of NK cell
|
MXPA06009759A
(en)
|
2004-02-27 |
2007-03-26 |
Pacmab Ltd |
Target for b-cell disorders.
|
JP2005336062A
(en)
|
2004-05-24 |
2005-12-08 |
Mitsubishi Chemicals Corp |
Homing inducer of t cell to intestinal tissue
|
FR2872170B1
(en)
|
2004-06-25 |
2006-11-10 |
Centre Nat Rech Scient Cnrse |
NON-INTERACTIVE AND NON-REPLICATIVE LENTIVIRUS, PREPARATION AND USES
|
US7147626B2
(en)
|
2004-09-23 |
2006-12-12 |
Celgene Corporation |
Cord blood and placenta collection kit
|
WO2007044033A2
(en)
|
2004-12-07 |
2007-04-19 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Therapeutic and diagnostic cloned mhc-unrestricted receptor specific for the muc1 tumor associated antigen
|
US8444973B2
(en)
|
2005-02-15 |
2013-05-21 |
Duke University |
Anti-CD19 antibodies and uses in B cell disorders
|
US8088908B2
(en)
|
2005-05-10 |
2012-01-03 |
City Of Hope |
Humanized anti-prostate stem cell antigen monoclonal antibody
|
KR20200123283A
(en)
|
2005-12-29 |
2020-10-28 |
안트로제네시스 코포레이션 |
Placental stem cell populations
|
CN101374941A
(en)
|
2005-12-29 |
2009-02-25 |
人类起源公司 |
Improved composition for collecting and preserving placental stem cells and methods of using the composition
|
AU2007211334A1
(en)
|
2006-02-01 |
2007-08-09 |
Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College |
Polypeptide-nucleic acid conjugate for immunoprophylaxis or immunotherapy for neoplastic or infectious disorders
|
CN101563104A
(en)
|
2006-02-01 |
2009-10-21 |
约翰霍普金斯大学 |
Polypeptide-nucleic acid conjugate for immunoprophylaxis or immunotherapy for neoplastic or infectious disorders
|
KR101571027B1
(en)
|
2006-06-12 |
2015-11-23 |
이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 |
Single-chain multivalent binding proteins with effector function
|
WO2008045437A2
(en)
|
2006-10-09 |
2008-04-17 |
The General Hospital Corporation |
Chimeric t-cell receptors and t-cells targeting egfrviii on tumors
|
SI2126054T1
(en)
|
2007-01-31 |
2016-12-30 |
Yeda Research And Development Company Limited |
Redirected, genetically-engineered t regulatory cells and their use in suppression of autoimmune and inflammatory disease
|
WO2008150853A1
(en)
|
2007-05-29 |
2008-12-11 |
Trustees Of Dartmouth College |
Compositions and methods for producing adaptive regulatory t cells
|
EP2167688A4
(en)
|
2007-06-12 |
2010-07-28 |
Univ Case Western Reserve |
Targeted cell death
|
EP2006376A1
(en)
|
2007-06-21 |
2008-12-24 |
Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH |
Fusion protein comprising a caspase domain and a nuclear hormone receptor binding domain and methods and uses thereof
|
KR101645311B1
(en)
|
2007-09-26 |
2016-08-03 |
안트로제네시스 코포레이션 |
Angiogenic cells from human placental perfusate
|
ES2530995T3
(en)
|
2007-09-28 |
2015-03-09 |
Anthrogenesis Corp |
Tumor suppression using human placental perfusate and intermediate natural killer cells that come from human placenta
|
WO2010003002A2
(en)
|
2008-07-02 |
2010-01-07 |
Board Of Regents, The University Of Texas System |
Modulation of follicular helper t cells
|
ES2961498T3
(en)
|
2008-08-26 |
2024-03-12 |
Hope City |
Method and compositions for enhanced performance of anti-tumor effect of T cells
|
EP2331680B1
(en)
|
2008-09-22 |
2017-05-03 |
Baylor College Of Medicine |
Methods and compositions for generating an immune response by inducing cd40 and pattern recognition receptor adapters
|
KR20110122859A
(en)
|
2009-02-23 |
2011-11-11 |
그렌마크 파머수티칼스 에스. 아. |
Humanized antibodies that bind to cd19 and their uses
|
PT2406284T
(en)
|
2009-03-10 |
2016-09-29 |
Biogen Ma Inc |
Anti-bcma antibodies
|
WO2010108126A2
(en)
|
2009-03-19 |
2010-09-23 |
Fate Therapeutics, Inc. |
Reprogramming compositions and methods of using the same
|
CA2774260C
(en)
|
2009-09-16 |
2018-10-09 |
Immunomedics, Inc. |
Class i anti-cea antibodies and uses thereof
|
WO2011035018A2
(en)
|
2009-09-18 |
2011-03-24 |
Fate Therapeutics, Inc. |
Suicide ready cells
|
EP2483301A1
(en)
|
2009-10-01 |
2012-08-08 |
The United States Of America, As Represented By The Secretary, Department of Health and Human Services |
Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer
|
US9181527B2
(en)
|
2009-10-29 |
2015-11-10 |
The Trustees Of Dartmouth College |
T cell receptor-deficient T cell compositions
|
EP2536706B1
(en)
|
2010-02-11 |
2017-06-14 |
Celgene Corporation |
Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
|
TW201134488A
(en)
*
|
2010-03-11 |
2011-10-16 |
Ucb Pharma Sa |
PD-1 antibodies
|
WO2011130566A2
(en)
|
2010-04-16 |
2011-10-20 |
Bellicum Pharmaceuticals, Inc. |
Method for treating solid tumors
|
US9089520B2
(en)
|
2010-05-21 |
2015-07-28 |
Baylor College Of Medicine |
Methods for inducing selective apoptosis
|
AU2011268110B2
(en)
|
2010-06-19 |
2016-05-19 |
Memorial Sloan-Kettering Cancer Center |
Anti-GD2 antibodies
|
NZ605505A
(en)
|
2010-07-13 |
2015-02-27 |
Anthrogenesis Corp |
Methods of generating natural killer cells
|
US9493740B2
(en)
|
2010-09-08 |
2016-11-15 |
Baylor College Of Medicine |
Immunotherapy of cancer using genetically engineered GD2-specific T cells
|
WO2012050374A2
(en)
|
2010-10-13 |
2012-04-19 |
Innocell, Inc. |
Immunotherapy for solid tumors
|
JP6109741B2
(en)
|
2010-10-27 |
2017-04-05 |
ベイラー カレッジ オブ メディスンBaylor College Of Medicine |
Chimeric CD27 receptor for directing T cells to CD70 positive malignancies
|
BR122021026169B1
(en)
*
|
2010-12-09 |
2023-12-12 |
The Trustees Of The University Of Pennsylvania |
USE OF A CELL
|
EA201391059A1
(en)
|
2011-01-18 |
2014-05-30 |
Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания |
COMPOSITIONS FOR CANCER TREATMENT AND METHODS OF THEIR APPLICATION
|
ES2841983T3
(en)
|
2011-03-23 |
2021-07-12 |
Hutchinson Fred Cancer Res |
Method and compositions for cellular immunotherapy
|
NZ723731A
(en)
|
2011-04-08 |
2020-05-29 |
Baylor College Medicine |
Reversing the effects of the tumor microenvironment using chimeric cytokine receptors
|
CA2832540C
(en)
|
2011-04-08 |
2020-09-15 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-epidermal growth factor receptor variant iii chimeric antigen receptors and use of same for the treatment of cancer
|
US20130071414A1
(en)
|
2011-04-27 |
2013-03-21 |
Gianpietro Dotti |
Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies
|
AU2012308205A1
(en)
|
2011-09-16 |
2014-03-13 |
The Trustees Of The University Of Pennsylvania |
RNA engineered T cells for the treatment of cancer
|
AU2012325915A1
(en)
|
2011-10-20 |
2014-04-24 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-CD22 chimeric antigen receptors
|
WO2013063419A2
(en)
|
2011-10-28 |
2013-05-02 |
The Trustees Of The University Of Pennsylvania |
A fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting
|
ES2861435T3
(en)
|
2011-11-03 |
2021-10-06 |
Univ Pennsylvania |
Specific compositions of isolated B7-H4 and methods of using them
|
WO2013070468A1
(en)
|
2011-11-08 |
2013-05-16 |
The Trustees Of The University Of Pennsylvania |
Glypican-3-specific antibody and uses thereof
|
EP2814846B1
(en)
|
2012-02-13 |
2020-01-08 |
Seattle Children's Hospital d/b/a Seattle Children's Research Institute |
Bispecific chimeric antigen receptors and therapeutic uses thereof
|
AU2013274416B2
(en)
|
2012-06-11 |
2019-07-04 |
Wilson Wolf Manufacturing, LLC |
Improved methods of cell culture for adoptive cell therapy
|
CN103483452B
(en)
|
2012-06-12 |
2021-08-13 |
上海细胞治疗集团有限公司 |
Dual signal independent chimeric antigen receptors and uses thereof
|
EP3904875A1
(en)
|
2012-06-29 |
2021-11-03 |
Celgene Corporation |
Methods for determining drug efficacy using ikzf3 (aiolos)
|
BR112015003149A2
(en)
|
2012-08-13 |
2017-08-08 |
Anthrogenesis Corp |
natural killer cells and uses thereof.
|
US11471486B2
(en)
|
2012-09-04 |
2022-10-18 |
Inven2 As |
Selective and controlled expansion of educated NK cells
|
CN112430580A
(en)
|
2012-10-02 |
2021-03-02 |
纪念斯隆-凯特琳癌症中心 |
Compositions and methods for immunotherapy
|
WO2014055657A1
(en)
|
2012-10-05 |
2014-04-10 |
The Trustees Of The University Of Pennsylvania |
Use of a trans-signaling approach in chimeric antigen receptors
|
AU2013204922B2
(en)
|
2012-12-20 |
2015-05-14 |
Celgene Corporation |
Chimeric antigen receptors
|
CA2904014C
(en)
|
2013-02-06 |
2021-06-15 |
Anthrogenesis Corporation |
Modified t lymphocytes having improved specificity
|
US9434935B2
(en)
|
2013-03-10 |
2016-09-06 |
Bellicum Pharmaceuticals, Inc. |
Modified caspase polypeptides and uses thereof
|
JP6541639B2
(en)
|
2013-03-14 |
2019-07-10 |
ベリカム ファーマシューティカルズ, インコーポレイテッド |
Methods to control T cell proliferation
|
EP3623380A1
(en)
|
2013-03-15 |
2020-03-18 |
Michael C. Milone |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
CA2907397C
(en)
|
2013-03-15 |
2022-11-22 |
Anthrogenesis Corporation |
Modified t lymphocytes
|
US9393268B2
(en)
|
2013-03-15 |
2016-07-19 |
Thomas Jefferson University |
Cell-based anti-cancer compositions with reduced toxicity and methods of making and using the same
|
ES2791598T3
(en)
|
2013-06-05 |
2020-11-05 |
Bellicum Pharmaceuticals Inc |
Methods to induce partial apoptosis using caspase polypeptides
|
JP6870988B2
(en)
|
2014-02-24 |
2021-05-19 |
セルジーン コーポレイション |
How to use cereblon activators for neuronal amplification and treatment of central nervous system disorders
|
JP6778114B2
(en)
|
2014-04-14 |
2020-10-28 |
アルビナス・オペレーションズ・インコーポレイテッドArvinas Operations, Inc. |
Imid-based proteolysis modulators and related uses
|
WO2016007506A1
(en)
|
2014-07-07 |
2016-01-14 |
Targazyme, Inc. |
Manufacture and cryopreservation of fucosylated cells for therapeutic use
|
EP3828267A3
(en)
|
2014-08-12 |
2021-08-11 |
Celgene Corporation |
Car-t lymphocytes engineered to home to lymph node b cell zone, skin, or gastrointestinal tract
|
US20180021378A1
(en)
|
2014-12-31 |
2018-01-25 |
Anthrogenesis Corporation |
Methods of treating hematological disorders, solid tumors, or infectious diseases using natural killer cells
|
CN108064283B
(en)
|
2015-02-24 |
2024-01-09 |
加利福尼亚大学董事会 |
Binding triggered transcription switches and methods of use thereof
|
US11331380B2
(en)
|
2016-10-20 |
2022-05-17 |
Celgene Corporation |
Cereblon-based heterodimerizable chimeric antigen receptors
|
MA46723A
(en)
|
2016-11-04 |
2019-09-11 |
Bluebird Bio Inc |
T CAR ANTI-BCMA LYMPHOCYTES COMPOSITIONS
|
EP3820515A1
(en)
|
2018-07-11 |
2021-05-19 |
Celgene Corporation |
Uses of anti-bcma chimeric antigen receptors
|